The CUORE Cryostat D’Addabbo, A.; Alduino, C.; Bersani, A. ...
Journal of low temperature physics,
12/2018, Letnik:
193, Številka:
5-6
Journal Article
Recenzirano
Odprti dostop
The Cryogenic Underground Observatory for Rare Events (CUORE) is a bolometric experiment for neutrinoless double-beta decay in
130
Te
search, currently taking data at the underground facility of ...Laboratori Nazionali del Gran Sasso (LNGS). The CUORE cryostat successfully cooled down a mass of about 1 ton at
∼
7
mK
, delivering a uniform and constant base temperature. This result marks a fundamental milestone in low-temperature detector techniques, opening the path for future ton-scale bolometric experiments searching for rare events. In this paper, we present the CUORE cryogenic infrastructure, briefly describing its critical subsystems.
Objective. To examine hepatitis C virus (HCV) seroprevalence among injection drug users in 4 US cities from 1994 through 2004. Methods. Demographic characteristics, behaviors, and prevalence of HCV ...antibody among 5088 injection drug users aged 18–40 years from Baltimore, Maryland; Chicago, Illinois; Los Angeles, California; and New York, New York, enrolled in 3 related studies—Collaborative Injection Drug User Study (CIDUS) I (1994–1996), CIDUS II (1997–1999), and CIDUS III/Drug User Intervention Trial (2002–2004)—were compared using the χ2 and Mantel-Haenszel tests of significance. Trends over time were assessed by logistic regression. Results. Prevalence of HCV infection was 65%, 35%, and 35% in CIDUS I, CIDUS II, and CIDUS III, respectively. The adjusted prevalence odds ratio (OR) of being HCV antibody positive increased with the number of years of injection drug use (OR, 1.93 95% confidence interval {CI}, 1.68–2.21 for each year of injecting within the first 2 years; OR, 1.09 95% CI, 1.07–1.11 for each year of injecting beyond the first 2 years). Significant decreases were observed in the prevalence of HCV antibody between CIDUS I and CIDUS III in Baltimore (OR, 0.30; 95% CI, 0.20–0.43) and Los Angeles (OR, 0.17; 95% CI, 0.09–0.31) and among people of races other than black in Chicago (OR, 0.12; 95% CI, 0.08–0.17). No decrease in prevalence was seen in New York (OR, 1.04; 95% CI, 0.69–1.58) or among blacks in Chicago (OR, 0.55; 95% CI, 0.16–1.90). Conclusion. Although regional differences exist, our data suggest that the incidence of HCV infection among injection drug users in the United States decreased from 1994 through 2004.
Increased pulse pressure, an indicator of conduit vessel stiffness, is a strong independent predictor of cardiovascular events in hypertensive cohorts, which suggests that reduction of conduit vessel ...stiffness may be desirable in hypertension.
We assessed changes in pulse pressure and conduit vessel stiffness in a 12-week double-blind, randomized clinical trial that compared monotherapy with the ACE inhibitor enalapril 40 mg daily (n=87) versus the vasopeptidase (dual ACE and neutral endopeptidase) inhibitor omapatrilat 80 mg daily (n=80) in patients with systolic hypertension. Patients were withdrawn from antihypertensive medications 1 to 2 weeks before enrollment, and systolic pressure was confirmed to be > or =160 mm Hg. With the use of calibrated tonometry and pulsed Doppler, pulsatile hemodynamics were assessed before randomization and at 12 weeks. Characteristic impedance (Z(c)), a direct measure of the stiffness of the central aorta, was calculated from the ratio of changes in carotid pressure and aortic flow in early systole. Omapatrilat compared with enalapril produced greater reductions in peripheral (-8.2+/-12.2 versus -4.0+/-12.2 mm Hg, P<0.05) and central (-10.2+/-16.2 versus -3.2+/-16.9 mm Hg, P<0.01) pulse pressures and Z(c) (237+/-83 to 208+/-70 versus 225+/-87 to 231+/-94 dyne x s/cm(5), P<0.001); the latter remained significant (P<0.05) after adjusting for change in mean pressure.
Greater reductions in pulse pressure and Z(c) in hypertensive subjects treated with omapatrilat compared with enalapril suggest that aortic stiffness is maintained by specific, partially reversible mechanisms and underscore a potential role for pharmacological modulation of natriuretic peptides in the treatment of hypertension.
Gibberella zeae (asexual state Fusarium graminearum) is a major causal agent of wheat head blight and maize ear rot in North America and is responsible for contamination of grain with deoxynivalenol ...and related trichothecene mycotoxins. To identify additional trichothecene biosynthetic genes, cDNA libraries were prepared from fungal cultures under trichothecene-inducing conditions in culture and in planta. A gene designated LH1 that was highly expressed under these conditions exhibited only moderate (59%) similarity to known trichothecene biosynthetic cytochrome P450s. To determine the function of LH1, gene disruptants were produced and assessed for trichothecene production. Gene disruptants no longer produced 15-acetyldeoxynivalenol, which is oxygenated at carbon 7 (C-7) and C-8, but rather accumulated calonectrin and 3-deacetylcalonectrin, which are not oxygenated at either C-7 or C-8. These results indicate that gene LH1 encodes a cytochrome P450 responsible for oxygenation at one or both of these positions. Despite the relatively low level of DNA and amino acid sequence similarity between the two genes, LH1 from G. zeae is the probable homologue of Tri1, which encodes a cytochrome P450 required for C-8 oxygenation in F. sporotrichioides.
Status and prospects for CUORE Canonica, L; Alduino, C; Alfonso, K ...
Journal of Physics. Conference Series (Online),
09/2017, Letnik:
888, Številka:
1
Journal Article, Conference Proceeding
Recenzirano
Odprti dostop
CUORE is a cryogenic detector consisting of 988 TeO2 crystals, 750 g each, and will be operated at a temperature of ∼10 mK, to search for neutrinoless double beta decay (0νββ) of 130Te. The detector, ...in the final stages of construction at the Laboratori Nazionali del Gran Sasso (Italy), will start its operations in 2016. CUORE-0, its pilot experiment, has proven the feasibility of CUORE, demonstrating that the target background of 0.01 counts/keV/kg/y and the energy resolution of 5 keV are within reach. CUORE-0 also made the most precise measurement of the 2νββ decay. The expected sensitivity of CUORE to the 0νββ 130Te half-life is 9 ·1025y, for 5 years of data taking. Here, we report the most recent results of CUORE-0, their implications for CUORE, and the current status of the CUORE experiment.
Correctional populations have an elevated human immuno-deficiency virus (HIV) prevalence, yet many individuals lack access to subspecialty care. Our study showed that HIV-infected inmates had ...significantly greater virologic suppression and higher CD4 T-lymphocyte counts when managed by a multidisciplinary team of subspecialists conducting clinics via telemedicine. In other studies, these outcomes have been associated with reductions on HIV-related morbidity and mortality, as well as HIV transmission.
•A large custom cryogen-free cryostat has been designed and built in order to operate the CUORE detector.•The CUORE cryostat has a 1 m3 experimental volume and is able to host a tonne-scale ...bolometric detector.•The CUORE cryostat guarantees a low noise and low radioactivity environment, needed to search for 0nbb.•The CUORE detector has been cooled down to 8.3 mK and steadily operated at 15 mK, proving the success of the cryostat.
The CUORE experiment is the world’s largest bolometric experiment. The detector consists of an array of 988 TeO2 crystals, for a total mass of 742 kg. CUORE is presently taking data at the Laboratori Nazionali del Gran Sasso, Italy, searching for the neutrinoless double beta decay of 130Te. A large custom cryogen-free cryostat allows reaching and maintaining a base temperature of ∼10 mK, required for the optimal operation of the detector. This apparatus has been designed in order to achieve a low noise environment, with minimal contribution to the radioactive background for the experiment. In this paper, we present an overview of the CUORE cryostat, together with a description of all its sub-systems, focusing on the solutions identified to satisfy the stringent requirements. We briefly illustrate the various phases of the cryostat commissioning and highlight the relevant steps and milestones achieved each time. Finally, we describe the successful cooldown of CUORE.
PDF
